# US 2024/0002844 A1 · Development of novel gene therapeutics for inflammation-induced bone loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002844 A1
- Document ID: US20240002844A1
- Status: Published application
- Kind: A1
- Application number: 18/021,901
- Filed: 2021-08-18
- Published: 2024-01-04
- Earliest claimed: 2020-08-19
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Jae-Hyuck Shim; Guangping Gao; Jun Xie; Yeon-Suk Yang
- Web page: https://patentgrep.com/patent/US20240002844A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 5/0654: {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
- C12N 15/86: Viral vectors
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2501/2317: Interleukin-17 (IL-17)
- C12N 2501/24: Interferons [IFN]
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2510/00: Genetically modified cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects of the disclosure relate to compositions and methods for reding inflammation and/or inhibiting bone loss (e.g., bone loss induced by inflammation). In some embodiments, the disclosure provides isolated nucleic acids and expression constructs (e.g., rAAVs, etc.) that encode one or more of the following transgenes: inhibitory nucleic acids targeting Schnurri 3 (SHN3), inhibitory nucleic acids targeting Cathepsin K (CTSK), inhibitory nucleic acids targeting sclerostin (SOST), inhibitory nucleic acids targeting receptor activator of NF-κβ (RANK), inhibitory nucleic acids targeting receptor activator of NF-κβ ligand (RANKL), soluble TNF-α Receptor 2 (sTNFR2), and soluble IL-1 Receptor Antagonist (sIL1Rα). In some embodiments, compositions described by the disclosure are useful for treating diseases associated with inflammation, for example rheumatoid arthritis (RA).

## Claims

### Claim 1

An isolated nucleic acid comprising a transgene comprising an osteoclast (OC)-specific promoter or an osteoblast (OB)-specific promoter operably linked to a nucleic acid sequence encoding one or more inhibitory nucleic acids targeting sclerostin (SOST), schnurri-3 (SHN3), cathepsin K (CTSK), receptor activator of NF-κβ, (RANK) and/or receptor activator of NF-κβ ligand (RANKL).

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the transgene further comprises a nucleic acid encoding a protein.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The isolated nucleic acid of claim 2, wherein the protein comprises soluble human tumor necrosis factor alpha receptor 2 (sTNRF2), a soluble IL-1 Receptor Antagonist (sIL1Rα), or sTNRF2 and sIL1Rα.

### Claim 5 (depends on 1)

The isolated nucleic acid of claim 1, wherein the OC-specific promoter comprises a NF-κβ promoter (e.g., RANK promoter) or wherein the OC-specific promoter is induced by inflammation, optionally wherein the NF-κβ promoter is a PB2 promoter (SEQ ID NO: 3).

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The isolated nucleic acid of claim 1, wherein the OB-specific promoter comprises an osteocalcin (OCN) promoter (SEQ ID NO: 4).

### Claim 8 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids is a shRNA, miRNA, or artificial miRNA (ami-RNA).

### Claim 9 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids is an ami-RNA comprising a human miRNA backbone, optionally a human miR-33 backbone.

### Claim 10 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids is an ami-RNA comprising a mouse miRNA backbone, optionally a mouse miR-33 backbone.

### Claim 11 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids targets SHN3, optionally wherein the inhibitory nucleic acid is encoded by a nucleic acid comprising the sequence set forth in any one of SEQ ID NOs: 8-11.

### Claim 12 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids targets CTSK, optionally wherein the inhibitory nucleic acid is encoded by a nucleic acid comprising the sequence set forth in any one of SEQ ID NOs: 20-25.

### Claim 13 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids targets SOST, optionally wherein the inhibitory nucleic acid is encoded by a nucleic acid comprising the sequence set forth in any one of SEQ ID NOs: 26-31.

### Claim 14 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids targets RANK.

### Claim 15 (depends on 1)

The isolated nucleic acid of claim 1, wherein at least one of the one or more inhibitory nucleic acids targets RANKL, optionally wherein the inhibitory nucleic acid is encoded by a nucleic acid comprising the sequence set forth in any one of SEQ ID NOs: 12-19.

### Claim 16 (depends on 1)

The isolated nucleic acid of claim 1, wherein the transgene encodes a first inhibitory nucleic acid targeting a gene selected from SHN3, CTSK, SOST, RANK, and RANKL; and a second inhibitory nucleic acid targeting a gene selected from SHN3, CTSK, SOST, RANK, and RANKL.

### Claim 17

An isolated nucleic acid comprising a transgene encoding a first inhibitory nucleic acid targeting a gene selected from SHN3, CTSK, SOST, RANK, and RANKL; and a second inhibitory nucleic acid targeting a gene selected from SHN3, CTSK, SOST, RANK, and RANKL.

### Claim at position 18

18-29. (canceled)

### Claim 30

An isolated nucleic acid comprising or encoding a sequence set forth in any one of SEQ ID NOs: 1-40.

### Claim at position 20

31-33. (canceled)

### Claim 34 (depends on 1)

A recombinant adeno-associated virus (rAAV) comprising:
(i) the isolated nucleic acid of claim 1; and
(ii) at least one AAV capsid protein.

### Claim at position 22

-39. (canceled)

### Claim 40 (depends on 34)

A method for inhibiting bone loss in a subject, the method comprising administering to the subject the rAAV of claim 34.

### Claim 41 (depends on 34)

A method for inhibiting inflammation in a joint of a subject, the method comprising administering to the subject the rAAV of claim 34.

### Claim 42 (depends on 34)

A method for treating rheumatoid arthritis in a subject, the method comprising administering to the subject the rAAV of claim 34.

### Claim at position 26

43-51. (canceled)
